Revista Espanola de Cardiologia Suplementos最新文献

筛选
英文 中文
Técnicas de imagen en la fibrilación auricular 心房颤动的成像技术
Revista Espanola de Cardiologia Suplementos Pub Date : 2016-01-01 DOI: 10.1016/S1131-3587(16)30010-3
José Antonio Vázquez de Prada , Leopoldo Pérez de Isla
{"title":"Técnicas de imagen en la fibrilación auricular","authors":"José Antonio Vázquez de Prada ,&nbsp;Leopoldo Pérez de Isla","doi":"10.1016/S1131-3587(16)30010-3","DOIUrl":"10.1016/S1131-3587(16)30010-3","url":null,"abstract":"<div><p>The aim of this review was to provide a practical guide to, and summary of, the imaging techniques currently available for evaluating patients with atrial fibrillation. In addition, the potential diagnostic, prognostic and therapeutic uses of these techniques are also discussed. This is a broad field in constant development. Nevertheless, today imaging is a vital aid to decision-making for patients with atrial fibrillation seen in routine clinical practice.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(16)30010-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56633623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Edoxabán. Propiedades farmacocinéticas y farmacodinámicas 爱德华。药代动力学和药效学特性
Revista Espanola de Cardiologia Suplementos Pub Date : 2016-01-01 DOI: 10.1016/S1131-3587(16)30017-6
Juan Tamargo
{"title":"Edoxabán. Propiedades farmacocinéticas y farmacodinámicas","authors":"Juan Tamargo","doi":"10.1016/S1131-3587(16)30017-6","DOIUrl":"10.1016/S1131-3587(16)30017-6","url":null,"abstract":"<div><p>Edoxaban is a potent, selective, direct, reversible inhibitor of coagulation factor Xa. Because of its mechanism of action, edoxaban prolongs the prothrombin time and the activated partial thromboplastin time and reduces anti-factor-Xa activity. In both in vitro and in vivo models, edoxaban is a more effective antithrombotic than fondaparinux. Given orally, the drug rapidly (i.e. in 1–2 hours) reaches its peak plasma concentration and achieves its maximum effect on various antithrombotic biomarkers (e.g. prothrombin time, activated partial thromboplastin time and anti-factor-Xa activity). Edoxaban (15–150 mg once daily) has a linear pharmacokinetic profile. It is readily absorbed when given orally (the bioavailability is 62%), but, unlike other factor-Xa inhibitors, it exhibits only poor binding to plasma proteins and is not biotransformed via CYP3A4. It is eliminated by biliary and renal routes and has a half-life of 10–14 hours, which enables edoxaban to be administered once daily. Exposure to the drug is independent of age, sex and ethnicity, but increases as the patient's weight and renal function decrease.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(16)30017-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56633980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Estudios en fase III del edoxabán 依多沙班的第三阶段研究
Revista Espanola de Cardiologia Suplementos Pub Date : 2016-01-01 DOI: 10.1016/S1131-3587(16)30019-X
Iñaki Lekuona Goya
{"title":"Estudios en fase III del edoxabán","authors":"Iñaki Lekuona Goya","doi":"10.1016/S1131-3587(16)30019-X","DOIUrl":"10.1016/S1131-3587(16)30019-X","url":null,"abstract":"<div><p>Edoxaban has been studied extensively in phase-III trials, for example, for nonvalvular atrial fibrillation (the ENGAGE AF-TIMI 48 study), for the prevention of recurrent venous thromboembolism (the Hokusai-VTE study) and for the prevention of thromboembolism after orthopedic surgery (the STARS study). In addition, a number of recently published, subanalyses of pivotal trials deserve consideration: these concern different subtypes of stroke and peripheral embolism in patients receiving amiodarone and the treatment of elderly patients.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(16)30019-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56634147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
¿Se está controlando las complicaciones del TAVI? TAVI并发症是否得到控制?
Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)30022-4
Enrique Gutiérrez, Rocío Angulo, Jaime Elízaga, Francisco Fernández-Avilés
{"title":"¿Se está controlando las complicaciones del TAVI?","authors":"Enrique Gutiérrez,&nbsp;Rocío Angulo,&nbsp;Jaime Elízaga,&nbsp;Francisco Fernández-Avilés","doi":"10.1016/S1131-3587(15)30022-4","DOIUrl":"10.1016/S1131-3587(15)30022-4","url":null,"abstract":"<div><p>Transcatheter aortic valve implantation is associated with a relatively high rate of complications, which can be serious in some cases. However, the improvements in device design and implantation techniques that have taken place since early experience with the procedure, combined with better understanding of possible complications and their risk factors, have contributed to a substantial reduction in the incidence of most complications. This article reviews recent findings on the most important complications of transcatheter aortic valve implantation.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(15)30022-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56632559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
La guía europea de dislipemia. Fortalezas y debilidades 欧洲血脂异常指南。优点和缺点
Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)70119-6
Eduardo Alegría-Ezquerra , Eduardo Alegría-Barrero , Ana Alegría-Barrero
{"title":"La guía europea de dislipemia. Fortalezas y debilidades","authors":"Eduardo Alegría-Ezquerra ,&nbsp;Eduardo Alegría-Barrero ,&nbsp;Ana Alegría-Barrero","doi":"10.1016/S1131-3587(15)70119-6","DOIUrl":"10.1016/S1131-3587(15)70119-6","url":null,"abstract":"<div><p>The joint guidelines of the European Society of Cardiology and the European Atherosclerosis Society on the management of dyslipidemia include a number of interesting clinical features: risk stratification provides the basis for selecting the type and intensity of lipid-lowering treatment; the principal therapeutic target is the low-density lipoprotein cholesterol level; the precise treatment target for this parameter depends on the level of risk (&lt;70<!--> <!-->mg/dl for very-high-risk patients and &lt;100<!--> <!-->mg/dl for high-risk patients); potent statins, given at a high dose, are the drugs of choice for achieving these goals; and particular recommendations must be followed for a number of common clinical scenarios: e.g. the elderly, women, patients with chronic kidney disease and secondary prevention.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(15)70119-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56633216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tratamiento de la insuficiencia cardiaca avanzada en el siglo XXI. El trasplante cardiaco en la encrucijada 21世纪晚期心力衰竭的治疗。心脏移植处于十字路口
Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)30002-9
Juan F. Delgado Jiménez
{"title":"Tratamiento de la insuficiencia cardiaca avanzada en el siglo XXI. El trasplante cardiaco en la encrucijada","authors":"Juan F. Delgado Jiménez","doi":"10.1016/S1131-3587(15)30002-9","DOIUrl":"10.1016/S1131-3587(15)30002-9","url":null,"abstract":"<div><p>Today heart transplantation is an accepted and established treatment for advanced heart failure. However, since the first procedure in Spain was performed in 1984, there have been substantial, unfavorable changes in donor and recipient profiles, as well as in the circumstances under which patients present for transplantation. These changes have taken place in parallel with medical and surgical advances in heart transplantation, such that, overall, outcomes have not been greatly affected. Nevertheless, it is important that the number of transplantations is either maintained or increased, that the good results obtained so far are sustained, that organs continue to be allocated as fairly as possible and that mortality among patients on the waiting list is reduced. This article considers the changes that have occurred in the field and reviews proposals for future improvements.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(15)30002-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85668466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TAVI: una revolución en cardiología
Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)30017-0
César Morís, Pablo Avanzas
{"title":"TAVI: una revolución en cardiología","authors":"César Morís,&nbsp;Pablo Avanzas","doi":"10.1016/S1131-3587(15)30017-0","DOIUrl":"10.1016/S1131-3587(15)30017-0","url":null,"abstract":"","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(15)30017-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83705633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Aspectos organizativos contemporáneos del trasplante cardiaco: visión del clínico 心脏移植的当代组织方面:临床医生的观点
Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)30004-2
Luis Alonso-Pulpón, Javier Segovia
{"title":"Aspectos organizativos contemporáneos del trasplante cardiaco: visión del clínico","authors":"Luis Alonso-Pulpón,&nbsp;Javier Segovia","doi":"10.1016/S1131-3587(15)30004-2","DOIUrl":"10.1016/S1131-3587(15)30004-2","url":null,"abstract":"<div><p>Heart transplantation in Spain achieved maturity some time ago in terms of outcomes and the number of procedures performed. The main limitation has been a lack of suitable donors. This article reviews strategies currently under discussion for achieving progress in the field, whether by increasing the number of donors, by more rational selection of transplant candidates or by better planning at the national level. The emergence of mechanical circulatory assist devices, used either as a complement or an alternative to transplantation, is the single factor that will have the greatest influence on heart transplantation in the future. Heart failure is a common, chronic and complex condition, whose treatment requires the cooperation of different tiers within the health-care system at the national level. Formal regional networks that enable such cooperation must be established, beginning with the adoption of common terminology. Of particular relevance is the network established for the integrated treatment of cardiogenic shock. Finally, the ongoing training of specialists in the field should be recognized officially. The Spanish Society of Cardiology should take the first steps on the regulatory path towards establishing certification in this subspecialty – this will help harmonize practice in the field of heart failure in Spain with that in other developed countries.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(15)30004-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56632391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Hipotermia terapéutica: ¿lo dejamos? 治疗性体温过低:我们应该停止吗?
Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)30029-7
Ana Viana Tejedor
{"title":"Hipotermia terapéutica: ¿lo dejamos?","authors":"Ana Viana Tejedor","doi":"10.1016/S1131-3587(15)30029-7","DOIUrl":"10.1016/S1131-3587(15)30029-7","url":null,"abstract":"<div><p>Current international guidelines recommend therapeutic hypothermia for patients who have survived a witnessed cardiac arrest to minimize neurological damage due to postischemic reperfusion. This recommendation is based mainly on the results of two randomized, controlled trials that included 352 patients and on supporting evidence from the field of neonatal asphyxia that also demonstrated the neuroprotective effect of hypothermia. However, the use of hypothermia in the context of a cardiac arrest has been called into question in the wake of a recently published randomized trial that included 939 patients and which found that hypothermia at 33 °C offered no benefits over maintaining a temperature of 36 °C. Moreover, another recent study has questioned the usefulness of starting hypothermia early in the prehospital phase. This article contains a review of the evidence available on the use of hypothermia, areas of uncertainty and strategies for using the technique. It concludes that there is sufficient evidence to support the continued use of hypothermia in the majority of patients who suffer a cardiac arrest and have a heart rhythm susceptible to defibrillation, pending the results of new studies using a range of target temperatures (32-36 °C) and treatment durations.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(15)30029-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56632451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Panorama actual del tratamiento farmacológico del paciente con enfermedad coronaria: de la teoría a la práctica 冠状动脉疾病患者药物治疗的现状概述:从理论到实践
Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(16)30003-6
Jesús Álvarez-García, Alessandro Sionis
{"title":"Panorama actual del tratamiento farmacológico del paciente con enfermedad coronaria: de la teoría a la práctica","authors":"Jesús Álvarez-García,&nbsp;Alessandro Sionis","doi":"10.1016/S1131-3587(16)30003-6","DOIUrl":"10.1016/S1131-3587(16)30003-6","url":null,"abstract":"<div><p>This article provides a brief review of the scientific evidence underpinning the pharmacological treatment of chronic stable coronary heart disease, of the extent to which cardiologists in the field follow European guidelines and of the degree of patients’ adherence to physicians’ recommendations. Finally, the article also discusses the clinical and economic implications of noncompliance with medical treatment and proposes some measures aimed at correcting these failings.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(16)30003-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56632967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信